Equal-WT
WhaleScore 2.0
?
Great Point Partners is based out of Greenwich. Great Point Partners is a hedge fund with 20 clients and discretionary assets under management (AUM) of $1,988,112,264 (Form ADV from 2024-10-14). Their last reported 13F filing for Q1 2025 included $188,796,269 in managed 13F securities
and a top 10 holdings concentration of 53.8%. Great Point Partners's largest holding is Cytokinetics Inc with shares held of 370,000. Whalewisdom has at least 57 13F filings, 31 13D filings, 416 13G filings, and 33 Form 4 filings
Business Description
Great Point consults an Advisory Board of limited partners of Clients for certain consents and approvals. Decisions of the Advisory Board are generally binding, but members owe no fiduciary duty to the Client and may act in the best interests of their affiliated investor. Although Great Point manages conflicts among Clients, Advisory Board members could have conflicts of interest that don't disqualify them from voting.
Great Point also provides investment advisory services to Public Equity Clients, who operate in the same industry as Private Equity Funds, potentially creating conflicts. Great Point believes this is mitigated by investing in different sub-sectors and dedicating personnel to the Private Equity Funds.
Investment Strategy
Each Hedge Fund aims for positive excess returns by investing in publicly traded biotechnology, pharmaceutical, and life science companies. Great Point believes a balanced portfolio of undervalued companies can yield above-average returns.
The Hedge Funds use a bottom-up, research-driven approach, investing in undervalued health care companies' securities. Securities are bought and sold in the open market and acquired through DNIs, often initiated by Great Point. Small and mid-cap stocks are the primary focus of the Hedge Funds' long exposure. Great Point may also modify or depart from its initial investment strategy.
Owners
- THE JAY FAMILY SPRAY TRUST - ASSOCIATED NON-MANAGING MEMBER
- JAY, JEFFREY, ROBERT - ELECTED MANAGER, MEMBER AND MANAGING DIRECTOR
- PANZIER, RONALD, MARC - CHIEF OPERATING OFFICER AND CHIEF FINANCIAL OFFICER
- Felsenthal, Adam, Brian - GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER Click on the Ownership/Private Fund Data tab for more details.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)
2025-03-31
Top Buys (13F)
| Name | % Change |
|---|---|
| AKBA Akebia Therapeutics | 5.06% |
| ASND Ascendis Pharma A/S | 4.13% |
| AMLX Amylyx Pharmaceutica | 3.4% |
| IMVT Immunovant Inc | 3.39% |
| SMMT Summit Therapeutics (PUT) | 2.55% |
2025-03-31
Top Sells (13F)
| Name | % Change |
|---|---|
| PLRX Pliant Therapeutics, | 5.94% |
| IONS Ionis Pharmaceutical | 4.33% |
| JSPR Jasper Therapeutics | 3.25% |
| ORKA Oruka Therapeutics I | 2.09% |
| OPTN Optinose Inc | 1.17% |
2025-03-31
13F Holdings Summary
| Name | $ Change |
|---|---|
| CYTK Cytokinetics Inc | 7.88% |
| KALV KalVista Pharmaceuti | 6.2% |
| EOLS Evolus Inc | 6.02% |
| ABVX Abivax | 5.42% |
| VRDN Viridian Therapeutic | 5.36% |
2025-03-31
13F Activity
| Market Value | $189m, Prior: $212m |
| Inflows (Outflows) as % of Total MV | +12.2876% |
| New Purchases | 10 stocks |
| Added To | 6 stocks |
| Sold out of | 4 stocks |
| Reduced holdings in | 8 stocks |
| Top 10 Holdings % | 53.8% |
| Turnover %[1] | 38.89% |
| Turnover Alt %[2] | 21.47% |
| Time Held Top 20 | 2.2 quarters |
| Time Held Top 10 | 1.9 quarters |
| Time Held All | 3.06 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2025-03-31
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2025-03-31
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2025-03-31